Abstract
Six patients received salvage treatment with posaconazole oral suspension (800 mg/day in divided doses) for severe forms of histoplasmosis. One patient had pulmonary disease and 5 had disseminated disease. Previous antifungal therapy consisted of amphotericin B, itraconazole, fluconazole, or voriconazole. Posaconazole treatment duration for individual patients ranged from 6 weeks to 34 weeks. All patients had successful clinical outcomes with significant clinical improvements noted during the first month of therapy. Although the number of patients evaluated in this case series is small, the findings are encouraging and provide preliminary evidence that posaconazole may be a useful salvage treatment option for histoplasmosis involving a variety of infected tissues and organs.
Publication types
-
Case Reports
-
Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged, 80 and over
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / adverse effects
-
Antifungal Agents / therapeutic use*
-
Cerebrospinal Fluid / microbiology
-
Ethmoid Sinusitis / drug therapy
-
Ethmoid Sinusitis / microbiology
-
Female
-
Histoplasma / drug effects*
-
Histoplasma / isolation & purification
-
Histoplasmosis / drug therapy*
-
Histoplasmosis / microbiology
-
Humans
-
Lung Diseases, Fungal / drug therapy
-
Lung Diseases, Fungal / microbiology
-
Male
-
Maxillary Sinusitis / drug therapy
-
Maxillary Sinusitis / microbiology
-
Meningitis, Fungal / drug therapy
-
Meningitis, Fungal / microbiology
-
Middle Aged
-
Salvage Therapy*
-
Treatment Outcome
-
Triazoles / administration & dosage
-
Triazoles / adverse effects
-
Triazoles / therapeutic use*
Substances
-
Antifungal Agents
-
Triazoles
-
posaconazole